ZYNLONTA Phase 3 Trial Meets Primary Endpoint, Mixed Safety Data Reported
ADCT is trading near its 52-week low of $2.55 (25% below the low).
Summary
ADC Therapeutics reported positive topline results from its Phase 3 LOTIS-5 trial for ZYNLONTA, meeting the primary endpoint of progression-free survival, but also disclosed a mixed safety profile with higher severe adverse events in the treatment arm. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA in Q4 2026.
Key Events · Product Development and Regulatory · ADCT
-
Phase 3 Trial Met Primary Endpoint
The LOTIS-5 confirmatory trial evaluating ZYNLONTA plus rituximab achieved its primary endpoint of progression-free survival (PFS) with statistical significance (HR = 0.73; p-value = 0.008).
-
Improved Efficacy Measures
The ZYNLONTA arm demonstrated higher overall response rate (58.1% vs. 45.2%), complete response rate (39.5% vs. 26.7%), and longer duration of complete responses (16.8 months vs. 12.3 months).
-
Mixed Safety Profile Reported
Higher rates of serious adverse events (49.0% vs. 34.5%), Grade 5 treatment-emergent adverse events (13.2% vs. 4.6%), and drug withdrawals (25.5% vs. 9.1%) were observed in the ZYNLONTA arm.
-
Planned Regulatory Submission
The company plans a pre-sBLA meeting with the FDA in August and intends to submit a supplemental Biologics License Application (sBLA) in the fourth quarter of 2026.
Analysis · ADCT · Life Sciences
ADC Therapeutics announced that its Phase 3 LOTIS-5 trial for ZYNLONTA in combination with rituximab met its primary endpoint of progression-free survival (PFS) with statistical significance. This is a crucial step towards full regulatory approval for the drug in relapsed or refractory DLBCL. While efficacy measures like overall response rate and complete response were also improved, the safety profile showed higher rates of serious adverse events, Grade 5 events, and drug withdrawals in the ZYNLONTA arm. The FDA's assessment of this benefit-risk profile will be critical for the planned sBLA submission in Q4 2026. This news comes as the company's stock trades near its 52-week low, and follows recent shareholder approval for increased authorized capital, suggesting a need for both clinical progress and financial optimization.
At the time of this filing, ADCT was trading at $1.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $391.7M. The 52-week trading range was $2.55 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.